Dont expect earnings to be much of a surprise.
Should be in line with estimates. What they
say in the conference call and if it generates
any interest is the key. Financing and
partnership news and broker coverage future
earnings estimates will be key. The reason
the stock rarely moves on FDA approvals is
that they dont do anything with pipeline or
approval